GLP-1 Program UK: What It Involves and How to Choose One (October 2026)

01 · The core answer

Is a GLP-1 program right for you?

A GLP-1 program is right for you if you are an adult who wants medically supervised weight management, is willing to change eating and activity habits, and can commit to regular reviews. It is not a quick fix. It is a structured course in which a prescriber decides whether the medicine is suitable, sets the dose, and checks how you are getting on.

The phrase is used loosely online. Some pages mean a clinical program built around a licensed medicine. Others mean a coaching or meal-plan subscription, a supplement bundle, an affiliate scheme that pays people to promote products, or a health-system scheme overseas. Only the first kind involves a regulated prescription medicine.

In the UK the medicine at the centre of most programs is tirzepatide, sold as Mounjaro. It is licensed for weight management in adults and is given as a once-weekly pen. Some programs use semaglutide (Wegovy) instead, and you can see how the two compare on our Wegovy pen page. Whichever medicine is used, the shape of a good program is the same: assessment, a slow step-up in dose, lifestyle support, monitoring, and a plan for what happens next.

02 · What to decide

The decisions you are actually facing

Most readers face three decisions. The first is whether to wait for the NHS or go private. Mounjaro is available on the NHS, but access is being phased in over several years, and the highest-need groups were first. If you do not fall into those groups yet, a regulated private program is a legitimate route, as long as a GPhC-registered prescriber reviews your suitability.

The second decision is how to judge providers. Look for a visible GPhC registration number, a real consultation reviewed by a prescriber rather than a tick-box script, genuine branded pens, and follow-up after the first dose. Be wary of anyone offering to supply without a consultation or prescription. Our own registration is GPhC 9012878, and you can check any pharmacy on the public register.

The third decision is cost over time. Because the dose steps up, the monthly price changes as you move through the pens. Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99), and every later order is £25 off the standard price. At standard prices, a first year (13 pens) costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg; a new customer's first order is £40 less and every later order £25 less. Prices checked 10 October 2026.

03 · Next step

What to do next

If you want a deeper comparison of providers, our guide to choosing a weight loss program sets out the questions to ask. When you are ready, the weight loss clinic page explains the free online consultation, which is reviewed by a GPhC-registered prescriber with no charge and no obligation.

Related guide: Cheapest glp 1 program.

04 · What a program includes

What a GLP-1 program includes

A proper GLP-1 program has several parts that work together, and if any are missing you are buying less than the name suggests. The parts are a suitability assessment, a licensed medicine, a dose plan, lifestyle guidance, and follow-up. Each does a different job, and none of them replaces the others.

The assessment comes first. You complete a health questionnaire, and a GPhC-registered prescriber reviews it. This is a clinical decision about whether the medicine is appropriate for you, your medical history and your other medicines. It is not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

The medicine itself is the second part. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ Needles, a sharps bin and injection guidance come with every order, so you are not left guessing how to use the pen.

The third part is the dose plan. Your prescriber decides when to move up, when to hold, and where you settle. That decision rests on how you feel and how you are responding, not on a fixed calendar.

The fourth part is lifestyle support. The medicine is used alongside a reduced-calorie diet and increased physical activity, and that is part of how it is licensed. A program that talks only about the injection and says nothing about food, movement, sleep or habits is incomplete. Our free companion app, GLPTrackr, helps you log your journey on iOS or Android, though it is a tracker rather than a clinician.

The fifth part is follow-up. Ongoing monthly reviews, dose-titration decisions and follow-up assessments by the prescribing team are what turn a single purchase into a program. Repeat orders re-check your suitability, and nothing ships automatically. You should also be able to reach a person when something goes wrong, such as an unexpected side effect, a delivery query or a missed dose. Our support team can be reached Monday to Friday by email, account chat or phone.

Finally, a program should say what happens at the end. Treatment may be long-term, but it does not have to be forever without review. A good provider talks about planned exits and maintenance from the first conversation, not as an afterthought.

When you compare programs, a simple test helps: could you describe, in a sentence each, who assesses you, what medicine you receive, how the dose changes, what lifestyle support you get, and who you call afterwards? If a provider cannot answer all five, keep looking.

05 · How the medicine works

How the medicine works inside a program

GLP-1 medicines work by acting on gut-hormone signals that control appetite and digestion. Understanding that helps you see why the program wraps habits around the injection rather than treating it as a magic switch.

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

That last point is the key to using a program well. The medicine makes eating less easier; it does not decide what you eat. People who use the quieter appetite to eat regular, protein-rich, mostly unprocessed meals tend to get more from treatment than those who simply skip meals.

Side effects are most likely when starting treatment or moving up a dose, and most are digestive, such as nausea, diarrhoea, vomiting, constipation and abdominal discomfort. This is one reason doses step up gradually. Your prescriber can slow the pace if you struggle, and you should tell the team rather than push on regardless.

The dual action is also what separates tirzepatide from single-action GLP-1 medicines such as semaglutide, sold as Wegovy or Ozempic. Ozempic is semaglutide licensed for type 2 diabetes — it is not a UK weight-loss medicine; the licensed weight-management options are Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg). Which suits you is a prescriber decision based on your history, your preferences and what you have tried. Our Mounjaro-specific program guide goes into the weekly routine in more detail.

The medicine is taken once a week, on the same day each week, which makes it easy to build into a routine. The weekly pattern matters because the medicine stays in your system for a long time. Tirzepatide has a half-life of about five days, so after a final dose it takes four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹

A different group of products, sold as daily injections, uses liraglutide at a concentration of 6mg per millilitre. It is a daily injection, unlike the once-weekly Mounjaro and Wegovy. Your prescriber can advise on how it compares for your situation.

Because Mounjaro slows stomach emptying, it can affect how quickly some oral medicines are absorbed, so your prescriber needs your full medication list.

06 · Who it suits

Who a GLP-1 program suits, and who it does not

A program suits adults whose weight affects their health and who want supervised treatment alongside lifestyle change. Whether you personally qualify is a prescriber decision, taken after reviewing your answers.

For private treatment, the medicine must be used within its licence, which is why a prescriber reviews your height, weight, health conditions and current medicines before approving anything. The reason for this care is simple: it is a prescription-only medicine, and the right answer differs from person to person.

Some people cannot take it or need extra caution. Your prescriber will ask about your medical history, any previous reactions, pregnancy plans, and other conditions, and will decline the order if the medicine is unsuitable. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. If an order is declined, it is refunded automatically in full. Be completely honest in the questionnaire. Leaving things out puts your safety at risk and defeats the point of the review.

You should also tell the prescriber about all your other medicines. Examples that matter: oral contraceptives, because the medicine can reduce their absorption as stomach emptying slows, and insulin or sulfonylureas, where doses may need adjusting because of low blood sugar risk.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ That does not mean these combinations are forbidden; it means your clinical team needs to plan them.

On the NHS, the picture is phased. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ If you want to know whether you qualify, ask your GP, and see the NHS guide to the medicine.⁵

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. Private treatment does not mean lower standards. The same medicine is used, and the same licence applies, but you pay for it and the assessment is done online.

Programs generally suit you best when you are ready to do three things: attend reviews, report side effects honestly, and work on food and activity. They suit you less well if you want a result with no change in habits, if you are looking for a short crash course, or if you are hoping to use the medicine for a cosmetic goal that does not fit its licence. A good provider will tell you that plainly.

Finally, remember that eligibility can change. A suitable program today may need a rethink if your health, medicines or circumstances change, which is another reason repeat orders are re-checked rather than shipped automatically.

07 · What results look like

What results look like in trials

Trial results show substantial average weight loss, but they are averages and your own result will differ.

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone. These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

Another way to read the same trial is by how many people reached a given threshold. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

To make the percentage tangible, take a worked example: for someone starting at 100 kg, 20.9% is about 21 kg. That is straight arithmetic of the trial average, not a prediction.

It is also important not to mix up trials. Different trials enrol different people, run for different lengths and use different designs, so their numbers should not be set side by side as if they were a head-to-head contest. SURMOUNT-5 is the trial that compares tirzepatide with semaglutide directly, and its result belongs in its own context.¹⁵

What should you take from all this? First, that these medicines work for many people when used as licensed. Second, that dose matters: the higher strengths showed larger average losses, but a higher dose is not automatically better for you, and many people do well at a lower maintenance dose agreed with their prescriber. Third, that nobody can promise a particular outcome, and any provider that promises specific results should be treated with suspicion.

Trial participants also received lifestyle support, which is the same combination a real program offers. If your program gives you a medicine and nothing else, you are not replicating the conditions in which these results were seen. Look for regular check-ins, practical diet advice, and activity guidance you can follow.

Finally, results are not only about the scale. Many people judge success by clothes, energy, joint comfort or health markers. Talk to your prescriber about what a good outcome means for you, so you have a clear target and a way to review it.

08 · Safety and side effects

Safety, side effects and interactions

GLP-1 medicines are licensed prescription medicines with known side effects, and a good program makes you aware of them before you start.

Side effects are most noticeable at the beginning and after dose increases, and most are digestive. Some people find them mild and others find them hard. Tell your prescriber early. They can slow the step-up, hold your dose, or advise on eating habits. In SURMOUNT-1, 4.3% of people on 5mg, 7.1% on 10mg and 6.2% on 15mg stopped treatment because of side effects, compared with 2.6% on placebo.² So most people stay on treatment, but a minority do stop, and that is a normal clinical outcome rather than a failure.

If you notice a new symptom that you are unsure about, do not assume it is harmless or that it is caused by the medicine. Speak to your prescriber, and report suspected side effects through the MHRA Yellow Card scheme, which anyone can use.¹⁹ If the symptom is severe or sudden, get medical help straight away.

Mental health is another area where you should speak up. Regulators have looked at whether GLP-1 medicines are linked to low mood or suicidal thoughts: the EMA's safety committee concluded in 2024 that the evidence does not support a causal link, and the MHRA keeps this under continuous review. Tell your prescriber about any history of depression, and seek help promptly if your mood drops or you have distressing thoughts during treatment.

If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

Interactions deserve attention too. Tell your prescriber about every medicine you take, including those you buy yourself. The medicine can reduce absorption of oral contraceptives, because stomach emptying slows. Switch to a non-oral method, or add a barrier method (such as condoms), for 4 weeks after starting and for 4 weeks after each dose increase.⁷ If you use insulin or sulfonylureas, doses may need adjusting because of the risk of low blood sugar. That is a reason for planned monitoring, not a reason to avoid treatment automatically.

Counterfeit medicine is a real risk when buying online. The MHRA publishes alerts about fake products, and the safest approach is to use a pharmacy you can find on the GPhC register, which you can check using the number on the provider's site.⁷ Our pens come through official LillyDirect supply, sourced directly from Eli Lilly's UK distribution, and are genuine KwikPens. Be wary of anyone offering to supply without a consultation or prescription, or selling pens that arrive without proper cold-chain packaging.

Storage is part of safety. Unopened pens are kept in the fridge at 2–8°C until first use, and they keep until the printed expiry date. Once in use, a KwikPen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Do not use a pen that has been above 30°C or has been frozen. Follow the leaflet for anything else.¹³ Our deliveries use temperature-controlled packaging for exactly this reason.

The overall message: these medicines are effective and widely used, but they are not risk-free and they are not for everyone. A program that explains this clearly, asks questions, and checks in with you is behaving responsibly.

09 · Stopping and maintenance

Stopping, maintenance and keeping weight off

Stopping a GLP-1 medicine often leads to some weight regain, so the end of treatment should be planned from the start. The evidence is clear about the direction, even though individual outcomes differ.

Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.¹⁴

That does not mean everyone must stay on treatment forever. It means the decision should be deliberate.

Remember that the medicine lingers after your last dose. It takes four to five weeks to clear, and nothing needs doing while that happens.¹ Appetite may creep back gradually over that period, so have your routine ready before the final dose, not afterwards.

Activity is central to maintenance. Increased physical activity is part of the licence, not an optional extra. Nothing special is required: the evidence-backed pattern is regular moderate activity (such as brisk walking) plus resistance work for muscle. Start where you are and build; on injection days with early side effects, lighter movement still counts. Exercise also protects against regain if you later stop treatment.

Food habits matter just as much. During treatment you have a window where appetite is quieter, and it is a good time to practise regular meals, sensible portions, enough protein and fewer ultra-processed foods. Habits built then are the ones that carry you through a lower dose or a break in treatment. Some people find that tracking helps, and our GLPTrackr app is free to use for that.

Regular reviews help here as well. Your prescribing team can talk through whether to hold your dose, reduce it or plan a break, based on how your weight, health and life are going. If you are weighing up a program, ask what it offers beyond the first few months, because maintenance is where many programs go quiet.

10 · Choosing an online program

How to choose an online GLP-1 program

The safest way to choose an online GLP-1 program is to check regulation first, clinical process second and price third. Many people do it the other way round and end up with a cheap deal from a source they cannot verify.

Start with registration. Any UK online pharmacy supplying prescription medicines should appear on the GPhC public register, and you can search by the registration number shown on the site.¹² Ours is GPhC 9012878. If a provider hides its registration, treat that as a warning.

Then look at the clinical process. A real consultation is reviewed by a prescriber, not scored automatically, and can end in a refusal. Ask what happens if you are unsuitable, how dose changes are decided, whether there are scheduled reviews, and who answers questions about side effects. We include ongoing monthly clinical reviews, and repeat orders re-check suitability, with no auto-shipping and no subscription lock-in.

Check the product. You want genuine branded pens, sourced from the manufacturer's distribution, with cold-chain delivery. Our Mounjaro is supplied through official LillyDirect supply and all six doses are in stock. Delivery is free and next-day, tracked and discreet, and orders in by 3pm are dispatched the same day. Saturday delivery is £14.99.

Watch for red flags: supplements marketed as natural versions of prescription medicines with dramatic weight-loss claims, sellers who do not need a consultation, pens sold without proper packaging, and promises of specific results. The MHRA runs a counterfeit alert service, and suspected fake products should be reported.⁷ Low-cost supplements have no clinical oversight and are not equivalent to licensed medicines.

On price, compare like with like. Across the UK pharmacies we track, the cheapest and dearest Mounjaro pens at any dose currently range from £143.96 to £339.00 per month, checked 10 October 2026. The gap between providers for the same dose ranges from £27 to £41. Our own standard prices are £169.99 for 2.5mg, £218.99 for 5mg, £279.99 for 7.5mg, £290.99 for 10mg, £319.99 for 12.5mg and £329.99 for 15mg, each per month.

Payment can be by Visa, Mastercard or Klarna, with pay-monthly options. If budget drives your choice, our guide to a more affordable route to treatment explains what to compare.

Ordering with us takes three steps: complete the free online consultation, wait for a GPhC-registered prescriber to review it, and then receive your dispensed pens by tracked delivery. For a wider introduction, see our blog on what UK weight loss programs involve. Prices checked 10 October 2026.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹